Trials / Completed
CompletedNCT00242346
High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to Severe Proteinuria
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 270 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effects of high doses of candesartan cilexetil and also to assess which dose (16mg, 64mg, 128mg) is the most optimal for the maximum reduction of proteinuria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | candesartan cilexetil |
Timeline
- Start date
- 2003-04-01
- Completion
- 2006-12-01
- First posted
- 2005-10-20
- Last updated
- 2007-12-19
Locations
26 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00242346. Inclusion in this directory is not an endorsement.